Form 4: Director Acquires PCSA Shares Under 10b5-1 Plan

Processa Pharmaceuticals Director Geraldine Pannu acquired 2,072 shares of common stock at $2.535 per share under a pre-arranged trading plan.

Summary

• Geraldine Pannu, a Director of Processa Pharmaceuticals, Inc. (PCSA), acquired 2,072 shares of the company's common stock.
• The transaction occurred on March 31, 2026, at a price of $2.535 per share.
• This acquisition was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Ms. Pannu directly beneficially owns a total of 2,188 shares of Processa Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's decision to increase their stake, even if small, suggests confidence in the company's future, especially when executed under a pre-planned arrangement.

Positives

• A director increasing their stake in the company can signal confidence in its future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition rather than a reaction to immediate news.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider buying, even in small amounts, can sometimes be interpreted by the market as a positive signal, especially when executed under a pre-arranged 10b5-1 plan, which suggests a long-term investment perspective rather than opportunistic timing.

Comparison to Industry Standards

• Insider transactions are a common occurrence across all industries, including the pharmaceutical sector.
• The size of this transaction (2,072 shares) is relatively modest compared to typical institutional purchases, but represents a direct increase in a director's personal stake.
• Many executives and directors in publicly traded companies, including biotech firms like Processa Pharmaceuticals, utilize Rule 10b5-1 plans to manage their stock holdings in compliance with insider trading regulations, a standard practice for corporate governance.

Corporate Governance

Related Party Transactions

• Geraldine Pannu, a Director of Processa Pharmaceuticals, Inc., acquired 2,072 shares of the company's common stock.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a positive sign of confidence in the company's future, potentially influencing investor sentiment.

Key Dates

Recommendation

The acquisition of shares by a director, particularly under a 10b5-1 plan, indicates management confidence in Processa Pharmaceuticals' future. While the transaction size is modest, it provides a positive signal for existing shareholders to hold their positions, suggesting internal belief in the company's value proposition.

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Stock Acquisition, Director, Geraldine Pannu, 10b5-1 Plan